D. Saralaya

Most-cited papers

1. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

   Obbina Ali Fatima Mustafa Sadia Hakam Alfie Nabeel Ashraf Abani Abbas Abbas Abbas Abbasi Abbass Abbott Abdal, O. Abani, A. Abbas, F. Abbas +496 more

   2021The Lancet1,685 citations Open access

   Semantic Scholar

   Save

2. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

   P. Heath, Eva P. Galiza, D. Baxter, M. Boffito +41 more

   2021New England Journal of Medicine799 citations Open access

   Semantic Scholar

   Save

3. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

   A. Munro, L. Janani, V. Cornelius, P. Aley +49 more

   2021The Lancet506 citations Open access

   Semantic Scholar

   Save

4. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

   R. A. O. C. M. O. H. J. C. A. A. M. R. M. V. C. L. R. P. C. E. J. S. G. N. N. Evans Leavy Richardson Elneima McAuley Shikotra Si, R. Evans, O. Leavy, M. Richardson +496 more

   2022The Lancet Respiratory Medicine308 citations Open access

   Semantic Scholar

   Save

5. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

   P. Monk, Richard J. Marsden, V. Tear, J. Brookes +28 more

   2020The Lancet Respiratory Medicine302 citations Open access

   Semantic Scholar

   Save

6. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

   Eugenia Mustafa Sadia Alfie Ashraf Sherif Mohamed Basir Al Abaleke Abbas Abbasi Abbott Abdelaziz Abdelbadiee , E. Abaleke, M. Abbas, Sadia Abbasi +496 more

   2021The Lancet289 citations Open access

   Semantic Scholar

   Save

7. Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant

   S. Toback, P. Heath, Eva P. Galiza, D. Baxter +41 more

   2021medRxiv283 citations Open access

   Semantic Scholar

   Save

8. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

   Obbina Ali Fatima Mustafa Sadia Hakam Alfie Nabeel Ashraf Abani Abbas Abbas Abbas Abbasi Abbass Abbott Abdal, O. Abani, A. Abbas, F. Abbas +496 more

   2021The Lancet141 citations Open access

   Semantic Scholar

   Save

9. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

   A. Munro, Shuo Feng, L. Janani, V. Cornelius +51 more

   2022Lancet. Infectious Diseases (Print)136 citations Open access

   Semantic Scholar

   Save

10. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

    O. A. F. J. K. M. S. H. A. Abani Abbas Abbas Abbas Abbas Abbas Abbasi Abbass, O. Abani, A. Abbas, F. Abbas +496 more

    2023The Lancet103 citations Open access

    Semantic Scholar

    Save

11. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

    Xin-Xue Liu, A. Munro, Shuo Feng, L. Janani +54 more

    2022Journal of Infection65 citations Open access

    Semantic Scholar

    Save

12. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

    P. Heath, Eva P. Galiza, D. Baxter, M. Boffito +41 more

    2022Clinical Infectious Diseases62 citations Open access

    Semantic Scholar

    Save

13. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)

    R. Niven, D. Saralaya, R. Chaudhuri, M. Masoli +5 more

    2016BMJ Open60 citations Open access

    Semantic Scholar

    Save

14. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

    J. Baillie, N. Lone, S. Jones, A. Shaw +496 more

    2023The Lancet Respiratory Medicine45 citations Open access

    Semantic Scholar

    Save

15. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Obbina Ali Fatima Mustafa Sadia Hakam Alfie Nabeel Ashraf Abani Abbas Abbas Abbas Abbasi Abbass Abbott Abdal, O. Abani, A. Abbas, F. Abbas +496 more

    2022The Lancet45 citations Open access

    Semantic Scholar

    Save

16. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

    Xin-Xue Liu, A. Munro, A. Wright, Shuo Feng +57 more

    2023Journal of Infection38 citations Open access

    Semantic Scholar

    Save

17. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.

    D. Saralaya, D. Peckham, B. Hulme, C. Tobin +3 more

    2004Journal of Antimicrobial Chemotherapy36 citations Open access

    Semantic Scholar

    Save

18. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.

    Ivan T. Lee, C. Cosgrove, Patrick Moore, C. Bethune +32 more

    2023Lancet. Infectious Diseases (Print)35 citations Open access

    Semantic Scholar

    Save

19. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

    Saul N. Faust, R. Haynes, C. Jones, N. Staplin +496 more

    2024The Lancet Child & Adolescent Health28 citations Open access

    Semantic Scholar

    Save

20. Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

    B. Zheng, G. Vivaldi, L. Daines, O. Leavy +496 more

    2023The Lancet Regional Health - Europe28 citations Open access

    Semantic Scholar

    Save

21. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.

    S. Andreas, M. Testa, L. Boyer, G. Brusselle +16 more

    2022The Lancet Respiratory Medicine28 citations Open access

    Semantic Scholar

    Save

22. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

    H. McAuley, R. A. Evans, C. Bolton, C. Brightling +496 more

    2023EClinicalMedicine23 citations Open access

    Semantic Scholar

    Save

23. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study

    R. Djukanović, P. Brinkman, J. Kolmert, C. Gómez +36 more

    2024American Journal of Respiratory and Critical Care Medicine21 citations Open access

    Semantic Scholar

    Save

24. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)

    A. Clemens, J. M. Marin, K. Beeh, W. Castellani +6 more

    2016International Journal of COPD18 citations Open access

    Semantic Scholar

    Save

25. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    O. A. F. J. K. M. S. H. A. Abani Abbas Abbas Abbas Abbas Abbas Abbasi Abbass, O. Abani, A. Abbas, F. Abbas +496 more

    2023The Lancet Diabetes and Endocrinology15 citations Open access

    Semantic Scholar

    Save

26. A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

    T. Wilkinson, Anthony De Soyza, M. Carroll, J. Chalmers +20 more

    2023ERJ Open Research13 citations Open access

    Semantic Scholar

    Save

27. Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial

    Dave Singh, J. Wild, D. Saralaya, Rod Lawson +12 more

    2022Respiratory Research13 citations Open access

    Semantic Scholar

    Save

28. Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST

    W. Busse, J. Máspero, C. Katelaris, D. Saralaya +12 more

    2018Allergy and immunology10 citations

    Semantic Scholar

    Save

29. Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    O. Abani, A. Abbas, F. Abbas, J. Abbas +496 more

    2025Lancet. Infectious Diseases (Print)9 citations Open access

    Semantic Scholar

    Save

30. Results of a phase 2b trial with GB001, a DP2 antagonist, in moderate-to-severe eosinophilic asthma.

    M. Moss, N. Lugogo, Mario Castro, N. Hanania +11 more

    2022Chest7 citations Open access

    Semantic Scholar

    Save

31. A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273

    Ivan T. Lee, C. Cosgrove, Patrick Moore, Claire Bethune +31 more

    2023medRxiv6 citations Open access

    Semantic Scholar

    Save

32. Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.

    Leila Janani, A. Munro, Annie Wright, P. Aley +51 more

    2025Journal of Infection5 citations Open access

    Semantic Scholar

    Save

33. The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insight

    Olivia Bird, Eva P. Galiza, D. Baxter, M. Boffito +34 more

    2024Epidemiology and Infection5 citations Open access

    Semantic Scholar

    Save

34. Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres

    M. Britton, T. Howes, A. Boland, D. Saralaya +5 more

    2011European Respiratory Journal3 citations

    Semantic Scholar

    Save

35. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

    O. A. F. J. K. M. S. H. A. Abani Abbas Abbas Abbas Abbas Abbas Abbasi Abbass, O. Abani, A. Abbas, F. Abbas +496 more

    2025EClinicalMedicine2 citations Open access

    Semantic Scholar

    Save

36. Adapting asthma clinical trials in response to the COVID-19 pandemic - the BenRex study design

    Steven Smith, Lynsey Gillespie, L. Heaney, C. Brightling +17 more

    2021Monitoring airway disease2 citations

    Semantic Scholar

    Save

37. Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study

    J. M. Marin, A. Clemens, R. Casamor, W. Castellani +6 more

    20152 citations

    Semantic Scholar

    Save

38. Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study

    D. Saralaya, A. Menzies-Gow, I. Clifton, A. Mansur +2 more

    2014European Respiratory Journal2 citations

    Semantic Scholar

    Save

39. Real-life Effectiveness Of Omalizumab In Patients With Severe Persistent Allergic (IgE-Mediated) Asthma At A Single UK Hospital

    A. Simons, K. Regan, Abid Aziz, D. Saralaya

    2010Asian Test Symposium2 citations

    Semantic Scholar

    Save

40. 2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial

    Ivan T. Lee, C. Cosgrove, Patrick Moore, M. Bula +24 more

    2023Open Forum Infectious Diseases1 citations Open access

    Semantic Scholar

    Save

41. Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]

    Xin-Xue Liu, A. Munro, Shuo Feng, L. Janani +54 more

    2023Journal of Infection1 citations Open access

    Semantic Scholar

    Save

42. Real life effectiveness of omalizumab in severe allergic asthma, does the IgE level matter? A Bradford experience

    Sandeep Jain, D. Saralaya, K. Regan, L. Walker

    2013European Respiratory Journal1 citations

    Semantic Scholar

    Save

43. Real-Life Effectiveness Of Omalizumab In Reducing Healthcare Utilization In Patients With Severe Persistent Allergic (IgE-Mediated) Asthma At A Single UK Hospital

    D. Saralaya, K. Regan, E. Rothwell, I. Kasujee

    2012Asian Test Symposium1 citations

    Semantic Scholar

    Save

44. Airway Inflammation and Asthma Control in Patients With Moderate Asthma Using Salbutamol or Budesonide/Formoterol Reliever: A Randomized, Controlled, Open-label Study

    M. Martín, I. Pavord, J. Chalmers, D. Saralaya +9 more

    2025American Journal of Respiratory and Critical Care Medicine0 citations

    Semantic Scholar

    Save

45. Immunogenicity and Reactogenicity of BNT162b2 and mRNA1273 COVID-19 Vaccines Given as Fourth Dose Boosters in the COV-BOOST Randomised Trial Following Two Doses of ChAdOx1 nCov-19 or BNT162b2 and a Third Dose of BNT162b2

    A. Munro, Shuo Feng, L. Janani, Victoria Cornelius +52 more

    2022Social Science Research Network0 citations

    Semantic Scholar

    Save

46. Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial

    S. Andreas, M. Testa, L. Boyer, G. Brusselle +16 more

    2021Airway pharmacology and treatment0 citations Open access

    Semantic Scholar

    Save

47. COVID19: a retrospective cohort study in Bradford with a focus on ethnicity

    Laura Smith, Nina K Pattabhiraman, Georgina Appleyard, I. Hutchesson +7 more

    2021Clinical problems0 citations

    Semantic Scholar

    Save

48. Recherche Omalizumab

    T. Howes, A. Boland, D. Saralaya, D. Hepburn +3 more

    20190 citations

    Semantic Scholar

    Save

49. Indacaterol/glycopyrronium increases lung ventilation in COPD patients as measured by hyperpolarized 3He MRI

    H. Tillmann, David Singh, D. Saralaya, R. Lawson +6 more

    2018Airway pharmacology and treatment0 citations

    Semantic Scholar

    Save

50. P19 Impact of month of initiation of omalizumab on treatment of severe allergic asthma, a sub-analysis of the apex ii study

    R. Niven, D. Saralaya, R. Chaudhuri, M. Masoli +5 more

    2017Thorax0 citations Open access

    Semantic Scholar

    Save